Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
161 hedge funds and large institutions have $685M invested in Aimmune Therapeutics in 2020 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 42 increasing their positions, 46 reducing their positions, and 38 closing their positions.
24% more call options, than puts
Call options by funds: $6.47M | Put options by funds: $5.23M
21% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 38
4% more funds holding
Funds holding: 155 → 161 (+6)
9% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 46
56% less capital invested
Capital invested by funds: $1.57B → $685M (-$885M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$39.5M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$25.7M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$19.6M |
| 4 |
AC
Armistice Capital
New York
|
+$15.3M |
| 5 |
Morgan Stanley
New York
|
+$11.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
-$51.1M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$40.4M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$32.6M |
| 4 |
Bank of New York Mellon
New York
|
-$11M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$11M |
AIMT Hedge Fund Activity: Q1 2020 in Review
161 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q1 2020, worth a combined $685M — down 56% from $1.57B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new AIMT positions and 38 closed out — a net gain of 8 holders — while 42 added to existing stakes and 46 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $39.5M. The largest seller was AllianceBernstein, cutting an estimated $51.1M.
- 161 institutional investors held Aimmune Therapeutics (AIMT) as of Q1 2020, up from 155 in Q4 2019.
- Funds reported $685M of Aimmune Therapeutics stock for Q1 2020, down 56% quarter-over-quarter.
- 46 funds opened new Aimmune Therapeutics positions in Q1 2020 and 38 closed out, a net change of +8 holders.
- The largest Aimmune Therapeutics buyer in Q1 2020 was Point72 Asset Management, an estimated $39.5M added.
- The largest Aimmune Therapeutics seller in Q1 2020 was AllianceBernstein, an estimated $51.1M sold.
Based on aggregated 13F filings for Q1 2020.